L1CAM expression in endometrial carcinomas: an ENITEC
collaboration study

J 2016

L1CAM expression in endometrial carcinomas: an ENITEC collaboration study

PUTTEN, L.J.M. van der; Nicole C. M. VISSER; Koen VIJVER; Maria SANTACANA; Peter BRONSERT et al.

Základní údaje

Originální název

L1CAM expression in endometrial carcinomas: an ENITEC collaboration study

Autoři

Vydání

British journal of cancer, LONDON, NATURE PUBLISHING GROUP, 2016, 0007-0920

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 6.176

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/16:00091707

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

endometrial cancer; endometrioid; non-endometrioid; L1CAM; immunohistochemistry

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 23. 11. 2016 15:43, Soňa Böhmová

Anotace

V originále

Background: Identification of aggressive endometrioid endometrial carcinomas (EECs) and non-endometrioid carcinomas (NEECs) is essential to improve outcome. L1 cell adhesion molecule (L1CAM) expression is a strong prognostic marker in stage I EECs, but less is known about L1CAM expression in advanced-stage EECs and NEECs. This study analyses L1CAM expression in a clinically representative cohort of endometrial carcinomas. Methods: The expression of L1CAM was immunohistochemically determined in 1199 endometrial carcinomas, treated at one of the European Network for Individualized Treatment of Endometrial Cancer (ENITEC) centres. Staining was considered positive when >10% of the tumour cells expressed L1CAM. The association between L1CAM expression and several clincopathological characteristics and disease outcome was calculated. Results: In all, L1CAM was expressed in 10% of the 935 stage I EECs, 18% of the 160 advanced stage EECs, and 75% of the 104 NEECs. The expression of L1CAM was associated with advanced stage, nodal involvement, high tumour grade, non-endometrioid histology, lymphovascular space invasion, and distant recurrences in all cases, and with reduced survival in the EECs, but not in the NEECs. Conclusions: The expression of L1CAM is a strong predictor of poor outcome in EECs, but not NEECs. It is strongly associated with non-endometrioid histology and distant spread, and could improve the postoperative selection of high-risk endometrial carcinomas. The value of L1CAM expression in the preoperative selection of high-risk endometrial carcinomas should be studied.

Citovat

PUTTEN, L.J.M. van der; Nicole C. M. VISSER; Koen VIJVER; Maria SANTACANA; Peter BRONSERT; Johan BULTEN; Marc HIRSCHFELD; Eva COLAS; Antonio GIL-MORENO; Angel GARCIA; Gemma MANCEBO; Fransesc ALAMEDA; Jone TROVIK; Reidun K. KOPPERUD; Jutta HUVILA; Stefanie SCHRAUWEN; Martin KOSKAS; Francine WALKER; Vít WEINBERGER; Luboš MINÁŘ; Eva JANDAKOVA; Marc P. L. M. SNIJDERS; Saskia VAN DEN BERG-VAN ERP; Xavier MATIAS-GUIU; Helga B. SALVESEN; Frederic AMANT; Leon F. A. G. MASSUGER a Johanna M. A. PIJNENBORG. L1CAM expression in endometrial carcinomas: an ENITEC collaboration study. British journal of cancer. LONDON: NATURE PUBLISHING GROUP, 2016, roč. 115, č. 6, s. 716-724. ISSN 0007-0920. Dostupné z: https://doi.org/10.1038/bjc.2016.235.

@article{1360530,
   author = {Putten, L.J.M. van der and Visser, Nicole C. M. and Vijver, Koen and Santacana, Maria and Bronsert, Peter and Bulten, Johan and Hirschfeld, Marc and Colas, Eva and GilandMoreno, Antonio and Garcia, Angel and Mancebo, Gemma and Alameda, Fransesc and Trovik, Jone and Kopperud, Reidun K. and Huvila, Jutta and Schrauwen, Stefanie and Koskas, Martin and Walker, Francine and Weinberger, Vít and Minář, Luboš and Jandakova, Eva and Snijders, Marc P. L. M. and van den Bergandvan Erp, Saskia and MatiasandGuiu, Xavier and Salvesen, Helga B. and Amant, Frederic and Massuger, Leon F. A. G. and Pijnenborg, Johanna M. A.},
   article_location = {LONDON},
   article_number = {6},
   doi = {https://doi.org/10.1038/bjc.2016.235},
   keywords = {endometrial cancer; endometrioid; non-endometrioid; L1CAM; immunohistochemistry},
   language = {eng},
   issn = {0007-0920},
   journal = {British journal of cancer},
   title = {L1CAM expression in endometrial carcinomas: an ENITEC collaboration study},
   volume = {115},
   year = {2016}
}

TY  - JOUR
ID  - 1360530
AU  - Putten, L.J.M. van der - Visser, Nicole C. M. - Vijver, Koen - Santacana, Maria - Bronsert, Peter - Bulten, Johan - Hirschfeld, Marc - Colas, Eva - Gil-Moreno, Antonio - Garcia, Angel - Mancebo, Gemma - Alameda, Fransesc - Trovik, Jone - Kopperud, Reidun K. - Huvila, Jutta - Schrauwen, Stefanie - Koskas, Martin - Walker, Francine - Weinberger, Vít - Minář, Luboš - Jandakova, Eva - Snijders, Marc P. L. M. - van den Berg-van Erp, Saskia - Matias-Guiu, Xavier - Salvesen, Helga B. - Amant, Frederic - Massuger, Leon F. A. G. - Pijnenborg, Johanna M. A.
PY  - 2016
TI  - L1CAM expression in endometrial carcinomas: an ENITEC collaboration study
JF  - British journal of cancer
VL  - 115
IS  - 6
SP  - 716-724
EP  - 716-724
PB  - NATURE PUBLISHING GROUP
SN  - 00070920
KW  - endometrial cancer
KW  - endometrioid
KW  - non-endometrioid
KW  - L1CAM
KW  - immunohistochemistry
N2  - Background: Identification of aggressive endometrioid endometrial carcinomas (EECs) and non-endometrioid carcinomas (NEECs) is essential to improve outcome. L1 cell adhesion molecule (L1CAM) expression is a strong prognostic marker in stage I EECs, but less is known about L1CAM expression in advanced-stage EECs and NEECs. This study analyses L1CAM expression in a clinically representative cohort of endometrial carcinomas. Methods: The expression of L1CAM was immunohistochemically determined in 1199 endometrial carcinomas, treated at one of the European Network for Individualized Treatment of Endometrial Cancer (ENITEC) centres. Staining was considered positive when >10% of the tumour cells expressed L1CAM. The association between L1CAM expression and several clincopathological characteristics and disease outcome was calculated. Results: In all, L1CAM was expressed in 10% of the 935 stage I EECs, 18% of the 160 advanced stage EECs, and 75% of the 104 NEECs. The expression of L1CAM was associated with advanced stage, nodal involvement, high tumour grade, non-endometrioid histology, lymphovascular space invasion, and distant recurrences in all cases, and with reduced survival in the EECs, but not in the NEECs. Conclusions: The expression of L1CAM is a strong predictor of poor outcome in EECs, but not NEECs. It is strongly associated with non-endometrioid histology and distant spread, and could improve the postoperative selection of high-risk endometrial carcinomas. The value of L1CAM expression in the preoperative selection of high-risk endometrial carcinomas should be studied.
ER  -

PUTTEN, L.J.M. van der; Nicole C. M. VISSER; Koen VIJVER; Maria SANTACANA; Peter BRONSERT; Johan BULTEN; Marc HIRSCHFELD; Eva COLAS; Antonio GIL-MORENO; Angel GARCIA; Gemma MANCEBO; Fransesc ALAMEDA; Jone TROVIK; Reidun K. KOPPERUD; Jutta HUVILA; Stefanie SCHRAUWEN; Martin KOSKAS; Francine WALKER; Vít WEINBERGER; Luboš MINÁŘ; Eva JANDAKOVA; Marc P. L. M. SNIJDERS; Saskia VAN DEN BERG-VAN ERP; Xavier MATIAS-GUIU; Helga B. SALVESEN; Frederic AMANT; Leon F. A. G. MASSUGER a Johanna M. A. PIJNENBORG. L1CAM expression in endometrial carcinomas: an ENITEC collaboration study. \textit{British journal of cancer}. LONDON: NATURE PUBLISHING GROUP, 2016, roč.~115, č.~6, s.~716-724. ISSN~0007-0920. Dostupné z: https://doi.org/10.1038/bjc.2016.235.

Přehled o publikaci